Topical permethrin plus oral ivermectin effective against common scabies

25 Sep 2021
Topical permethrin plus oral ivermectin effective against common scabies

The combination of topical permethrin and oral ivermectin is an effective treatment for common scabies, a new study has found. However, post-scabetic itch seems to persist longer than has been previously thought, particularly in older adults.

The single-centre retrospective cohort study included 55 common scabies patients (mean age 55 years, 49 percent women) who had been treated with topical permethrin and oral ivermectin. Clinical outcome at follow-up, the primary endpoint, was categorized as cured, worsening, or no change. A parallel group of 48 patients treated with permethrin alone was also included for comparison.

After a median of 18 days, 49 patients treated with the combination approach were deemed cured, yielding a rate of 89 percent. Cure was defined as a decrease in clinical lesions after completion of intervention. In the permethrin group, 46 patients achieved this benchmark, corresponding to a rate of 96 percent (p=0.44). One patient in the combination group had worsening symptoms.

Similarly, there were no significant between-group differences in terms of time from treatment to cure, duration of follow-up after cure, recurrence, and duration of post-scabetic itch.

Notably, post-scabetic itch was a common occurrence, developing in 34 percent (n=35) of the overall cohort. Such itch persisted for a median of 52.5 days and participants had to dedicate a median of 1 follow-up visit for it.

Post-scabetic itch incidence tended to be higher in those who received the combination therapy, though failed to reach significance (p=0.072). Since this group was older by a mean of 13 years, the researchers “hypothesize that age-related physiologic changes … may contribute to this observed trend.”

“Future larger studies are needed to evaluate the role of aging in post-scabetic itch, treatment strategies for mitigating post-scabetic itch, and the relevance of fomite control measures in clinical disease management of scabies,” they added.

Int J Womens Dermatol 2021;doi:10.1016/j.ijwd.2021.09.001